A highly motivated clinical research scientist with 5+ years of clinical development and medical affairs experience working in the hematology and immuno-oncology therapeutic areas.
Yacoub A, Andorsky DJ, Coleman M, Melear J, Brooks H, Fanning S, Kolibaba K, Lansigan F, Reynolds C, Li J, Liu D, Llorente M, Abbas A, Ricker JL, Rummel MJ, Sharman J. Response to lenalidomide plus rituximab (R2) is independent of rituximab-refractory status and number of prior lines of therapy: interim analysis of initial treatment phase of MAGNIFY IIIB study of R2 followed by extended treatment in relapsed/refractory indolent non-hodgkin lymphoma. Poster presented at: Pan Pacific Lymphoma Conference; 2018 July 16-20; Maui, HI
Springfield First Aid Squad: Springfield, NJ; March 2017 – Present
Volunteer EMT: August 2018 – Present
Supply Sgt: January 2019 – December 2019
Deputy Chief: January 2020 – Present
Companies Worked For:
Job Titles Held: